Driver gene negative non-small cell lung cancer, urothelial carcinoma, esophageal cancer, nasopharyngeal carcinoma, melanoma, renal cell carcinoma, small cell lung cancer, triple-negative breast cancer, hepatocellular carcinoma, renal cell carcinoma, small cell lung cancer, triple-negative breast cancer, hepatocellular carcinoma
Conditions
Interventions
Toripalimab experimental group:None
Sponsors
Yantai Yuhuangding Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Pathologically or cytologically confirmed as the corresponding solid tumor (driver gene-negative non-small cell lung cancer, urothelial carcinoma, esophageal cancer, nasopharyngeal carcinoma, melanoma, renal cell carcinoma, small cell lung cancer, triple-negative breast cancer, hepatocellular carcinoma); 2. Based on the TNM stage being advanced (TXNXM1), or the locally advanced stage applicable for systemic treatment; 3. There is at least one lesion that can be evaluated by CT or MRI; 4. Patients who have completed at least 3 cycles of toripalimab monotherapy and/or combination therapy; 5. At least one effectiveness assessment (imaging assessment 6 to 12 weeks after the first administration) has been completed; 6. The subjects voluntarily joined this study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Having suffered from other malignant tumors within the past five years, except for localized tumors that have been cured through research. 2. Patients who participated in other clinical trials during the observation period; 3. This study is a real-world one and there are no special exclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Progression-free survival; | — |
Countries
China
Contacts
Public ContactCheng Yu
Yantai Yuhuangding Hospital
Outcome results
None listed